India, June 11 -- Propanc Biopharma, Inc. (PPCB) has authorized a share repurchase program allowing the company to buy back up to $5.0 million of its common stock. Management said the decision reflects growing confidence in the company's progress as it advances PRP, its lead therapeutic candidate, toward first-in-human clinical evaluation.
The company noted that PRP, a first-in-class cancer therapy for the treatment and prevention of metastatic cancer from solid tumors, is moving toward a pivotal Phase 1b study in 30 to 40 advanced cancer patients. Propanc said recent work-including publishing scientific data, filing patentable discoveries, forming partnerships with CRO's, CDMO's and suppliers- has positioned the program for meaningful cli...